leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...102103104105106107108109110111112...235236»
  • ||||||||||  Avastin (bevacizumab) / Roche, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap
    Clinical, Journal:  Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience. (Pubmed Central) -  Feb 26, 2022   
    Furthermore, the risk of hematologic and nonhematologic adverse reactions significantly increased, and the risk of digestive-tract and hematologic toxicity was more significant. Although no statistically significant differences have been found in TT or PFS, it would be more advisable to use BFIR scheme due to its better results in OS and toxicity profile.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Retrospective data, Review, Journal, Adverse events, Serious adverse event:  Tolerability on Serious Adverse Events of First-Line Bevacizumab and Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Feb 26, 2022   
    First-line bevacizumab-based chemotherapy substantially lowered the risks of adverse events related to the dermatological (RR 0.24, 95% CI: 0.11-0.53, p < 0.00001) and renal systems (RR 0.57, 95% CI: 0.37-0.86, p = 0.007), while significantly increasing the incidence of cardiovascular adverse events (RR 4.65, 95% CI: 1.83-11.78, p = 0.001). Thus, first-line cetuximab-based chemotherapy increases patient susceptibility to dermatological and renal adverse events, especially with rash and electrolyte disorders, whereas bevacizumab-based chemotherapy increases cardiovascular risks such as hypertension and arrhythmia.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Supportive Oncology Care at Home Intervention for Patients with Pancreatic Cancer (Anaheim Convention Center - Learning Hall: Poster Pavilion) -  Feb 25, 2022 - Abstract #ONS2022ONS_603;    
    These findings demonstrate the feasibility and acceptability of a Supportive Oncology Care at Home intervention. Future work will investigate the efficacy of this intervention for decreasing healthcare use and improving outcomes for all patients dealing with cancer.
  • ||||||||||  methotrexate / Generic mfg.
    Ambulatory Methotrexate (Anaheim Convention Center - Learning Hall: Poster Pavilion) -  Feb 25, 2022 - Abstract #ONS2022ONS_269;    
    Development of documentation tools for patients that are easy to understand, along with scheduled ambulatory monitoring visits, allow patients to receive an inpatient regimen in the outpatient setting safely. Innovation: Utilizing the interdisciplinary team to create a safe process has helped our institution move to the next level in ambulatory care.
  • ||||||||||  mitomycin / Generic mfg.
    Q&A (Coronado) -  Feb 25, 2022 - Abstract #SSO2022SSO_413;    
    Learning Objectives: appreciate that a significant portion of patients who undergo CRS-HIPEC are exposed to neoadjuvant Oxaliplatin therapy. appreciate that exposure to neaodjuvant Oxaliplatin does not have any impact on survival following CRS-HIPEC as stratified by perfusion agents.
  • ||||||||||  Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
    Q&A (Chantilly East) -  Feb 25, 2022 - Abstract #SSO2022SSO_286;    
    In the absence of concordance between the 3 types of response, biochemical response (CA19-9 decrease by > 25%) best predicts long-term survival. Learning Objectives: Upon completion, participants are expected to list three measures of the effectiveness of neoadjuvant therapy in resected pancreatic cancer.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    S-adenosylmethionine Protects Against Folfox-induced Liver Injury (Trinity Ballroom) -  Feb 25, 2022 - Abstract #SSO2022SSO_245;    
    Lack of PAI-1 appears to protect from FOLFOX-induced SOS. Further studies investigating the cell type of origin of PAI-1 associated with FOLFOX induced liver injury is warranted.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Q&A (Trinity Ballroom) -  Feb 25, 2022 - Abstract #SSO2022SSO_238;    
    Lack of PAI-1 appears to protect from FOLFOX-induced SOS. Further studies investigating the cell type of origin of PAI-1 associated with FOLFOX induced liver injury is warranted.
  • ||||||||||  Jakafi (ruxolitinib) / Incyte
    Trial primary completion date:  AALL1521: A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Feb 24, 2022   
    P2,  N=170, Recruiting, 
    The observed profound negative effects of this chemotherapy drug cocktail on myotubes underlie a need for approaches that can reduce the negative effects of these drugs on muscle metabolism. Trial primary completion date: Feb 2024 --> Dec 2024
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Retrospective data, Review, Journal:  Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis. (Pubmed Central) -  Feb 23, 2022   
    Various first-line chemotherapy treatment regimens for patients with metastatic pancreatic cancer have been approved in Japan, including gemcitabine (GEM); fluorouracil, leucovorin, irinotecan, and oxaliplatin combination (FOLFIRINOX); GEM plus albumin-bound paclitaxel (GEM+NPTX), and S-1 (tegafur + gimeracil + oteracil)...The curve estimation also showed that FOLFIRINOX had the largest AUC for survival at 15.49 person-months (range, 13.84-15.51 person-months), followed by GEM+NPTX with 12.36 person-months (range, 10.98-12.59 person-months), GEM+ERLO with 10.84 person-months (range, 9.66-11.23 person-months), S-1 with 8.44 person-months (range, 8.26-9.74 person-months), and GEM with 8.10 person-months (range, 7.93-9.38 person-months). The results of this network meta-analysis support the relative short-term and long-term outcomes associated with first-line chemotherapy for metastatic pancreatic cancer used clinically in Japan.